NTHI — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-10

• NeOnc’s lead product candidate is NEO100. NEO100 is administered to patients via intranasal delivery. We have completed human safety testing in a Phase 1 clinical trial and have completed patient enrollment in, and the collection of clinical data from, our Phase 2a trial in patients with recurrent m…

• These factors raise substantial doubt regarding the Company’s ability to continue as a going concern one year from the issuance date of this Form 10-Q. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

• The Company is actively taking steps to mitigate the substantial doubt about the Company’s ability to continue as a going concern, including pursuing additional financing. If the Company is unable to obtain additional capital and continue as a going concern, it may have to further scale back operati…

• ● license fees and milestone payments made pursuant to license and collaboration agreements; and

• Loss on change in fair value of derivative liability related to Series A preferred stock (61,321 ) - (61,321 )

Text removed vs the prior filing · source: 10-Q · 2026-05-15

• NeOnc’s lead product candidate is NEO100. NEO100 is administered to patients via intranasal delivery. We have completed human safety testing in a Phase 1 clinical trial and are currently conducting preliminary efficacy testing in a Phase 2a trial with recurrent malignant glioma (Grade IV IDH1 mutant…

• We have concluded that there is substantial doubt about our ability to continue as a going concern for at least one year from the date of issuance of the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

• Gain on change in fair value of derivative liability 2,801 - 2,801

• No revenue was generated for fees for a “right to try” humanitarian program during the three months ended March 31, 2026. Revenue of $39,990 was generated during the three months ended March 31, 2025 from fees related to a “right to try” humanitarian program.

• Legal and professional expenses were $1,188,220 and $957,545 for the three months ended March 31, 2026 and 2025, respectively. The increase of $230,675 was primarily attributable to investment banking fees and incremental legal and audit fees incurred in connection with the preparation and filing of…

Text added vs the prior filing · source: 10-Q · 2026-08-10

• ● implemented a new enterprise resource planning system, migrating our accounting records and financial close processes from QuickBooks Online to NetSuite, to enhance the design and operation of controls over our chart of accounts, transaction-level account mapping, and financial reporting processes…